<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01113658</url>
  </required_header>
  <id_info>
    <org_study_id>SNaP-113009</org_study_id>
    <nct_id>NCT01113658</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the SNaP Wound Care System</brief_title>
  <official_title>Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KCI USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of design improvements of the Spiracur&#xD;
      SNaP Wound Care System. This study prospectively evaluates the safety and efficacy of current&#xD;
      and new design iterations of components of the FDA-cleared Spiracur SNaP Wound Care System in&#xD;
      order to optimize safety, efficacy, and system performance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was terminated by Spiracur (original sponsor). Efforts were made to contact the&#xD;
    PI/study team members, but were unsuccessful.&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2010</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of complaints about device use and operation</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute and Chronic Wounds</condition>
  <condition>Pressure Ulcers</condition>
  <condition>Trauma Wounds</condition>
  <condition>Diabetic Foot Ulcers</condition>
  <condition>Venous Stasis Ulcers</condition>
  <arm_group>
    <arm_group_label>SNaP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SNaP disposable, mechanically powered Negative Pressure Wound Therapy System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SNaP Wound Care System</intervention_name>
    <description>The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.&#xD;
The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician.</description>
    <arm_group_label>SNaP</arm_group_label>
    <other_name>Spiracur SNaP Wound Care System</other_name>
    <other_name>SNaP</other_name>
    <other_name>The SNaP System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Wound &lt; 10 cm in greatest diameter&#xD;
&#xD;
          -  Patient &gt;18 years of age&#xD;
&#xD;
          -  Willing and able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with wound-related cellulitis&#xD;
&#xD;
          -  Patients with thick eschar at wound base post debridement&#xD;
&#xD;
          -  Patients with wounds located in an area not amenable to forming an air- tight seal&#xD;
&#xD;
          -  Ulcers due to inflammatory conditions such as pyodermagangrenosum, rheumatoid&#xD;
             arthritis, vasculitis, cryoglobulinemia, necrobiosislipoidicadiabeticorum, lupus or&#xD;
             pancreatic panniculitis, cryofibrinogenemia, calcinosis cutis, scleroderma, Raynaud's&#xD;
             syndrome&#xD;
&#xD;
          -  Patient has untreated osteomyelitis&#xD;
&#xD;
          -  Patient is allergic to wound care products&#xD;
&#xD;
          -  Patient wounds with exposed blood vessels not suitable for negative pressure therapy&#xD;
&#xD;
          -  Pregnant or pregnancy-suspected patients&#xD;
&#xD;
          -  Subject actively participating in other clinical trials that conflict with the current&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristine K Nemes, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seton Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Center for Advanced Wound Care</name>
      <address>
        <city>Daly City</city>
        <state>California</state>
        <zip>94015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The SF Center For Advanced Wound Care At</name>
      <address>
        <city>Daly City</city>
        <state>California</state>
        <zip>94015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>April 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2010</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>negative pressure wound therapy</keyword>
  <keyword>NPWT</keyword>
  <keyword>Spiracur</keyword>
  <keyword>SNaP Wound Care System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Pressure Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

